



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, December 12, 2022

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces the payment of \$10 million from Janssen Products LP (Janssen), after reaching a commercial milestone in relation to Yondelis® (trabectedin) in the United States as defined in the licensing agreement.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar receives US\$10 million milestone payment from Janssen

- The Company entered into a new licensing agreement with Janssen in August 2019 for the marketing and distribution of Yondelis® in the USA.

Madrid, December 12th, 2022.- PharmaMar (MSE:PHM) has announced today receipt of a payment of \$10 million from Janssen Products LP after reaching a commercial milestone for Yondelis® (trabectedin) in the United States as defined in the licensing agreement.

In August 2019, PharmaMar entered into a new licensing agreement with Janssen, which replaced a 2001 licensing agreement, under which Janssen retained the right to sell and distribute, on an exclusive basis, Yondelis® in the USA.

Today, Yondelis® is approved in more than 70 countries for the treatment of soft tissue sarcoma and in some of these countries ovarian cancer as well.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca® and ecubectedin. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at pharmamar.com

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting



active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno – Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at pharmamar.com